Call for Abstract
3rd International Conference and Expo on Drug Discovery & Designing, will be organized around the theme “The developmental strategies and Various new advances in Drug Discovery and Designing through a decade in Europe”
Drug Discovery 2017 is comprised of keynote and speakers sessions on latest cutting edge research designed to offer comprehensive global discussions that address current issues in Drug Discovery 2017
Submit your abstract to any of the mentioned tracks.
Register now for the conference by choosing an appropriate package suitable to you.
The field of structure-based drug design is a rapidly growing area in which many successes have occurred in recent years. The explosion of genomic, proteomic, and structural information has provided hundreds of new targets and opportunities for future drug lead discovery. This review summarizes the process of structure-based drug design and includes, primarily, the choice of a target, the evaluation of a structure of that target, the pivotal questions to consider in choosing a method for drug lead discovery, and evaluation of the drug leads. Key principles in the field of structure-based drug design will be illustrated through a case study that explores drug design for AmpC β-lactamase.Drug Discovery Informatics Market size was USD 1.6 billion in 2015 and is anticipated to reach around USD 6.5 billion by 2023.
- Track 1-1Research & Development in Drug Designing
- Track 1-2Drug Targets
- Track 1-3Drug Designing Docking
- Track 1-4Types of Drug Design
- Track 1-5Structural based drug designing.
- Track 1-6Virtual screening.
In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which new candidate medications are discovered. Historically, drugs were discovered through identifying the active ingredient from traditional remedies or by serendipitous discovery. Later chemical libraries of synthetic small molecules, natural products or extracts were screened in intact cells or whole organisms to identify substances that have a desirable therapeutic effect in a process known as classical pharmacology.The global market for drug discovery technologies and products was worth $38.4 billion in 2011. This figure is projected to reach $41.4 billion in 2012 and $79 billion in 2017, a five-year compound annual growth rate (CAGR) of 13.8%.
- Track 2-1Pharmacogenetics in Drug Discovery and Development
- Track 2-2Advancing Drug Discovery
- Track 2-3Pharmaceutical Industry Perspective
- Track 2-4Historical Perspective
- Track 2-5Accelerated Drug Discovery Perspectives
- Track 2-6Flexible ligand docking.
Computer-aided drug design uses computational chemistry to discover, enhance, or study drugs and related biologically active molecules. The fundamental goal is to predict whether a given molecule will bind to a target and if so how strongly. CADD entails use of computing power to streamline drug discovery and development process, leverage of chemical and biological information about ligands and/or targets to identify and optimize new drugs, design of in silico filters to eliminate compounds with undesirable properties (poor activity and/or poor Absorption, Distribution, Metabolism, Excretion and Toxicity, ADMET) and select the most promising candidates.The biosimulation market is expected to reach USD 2,107.99 Million by 2020 from USD 1,034.93 Million in 2015, growing at a CAGR of 15.29% between 2015 and 2020.
- Track 3-1Steps Involved in CADD
- Track 3-2Drug Design Software
- Track 3-3Biomarkers
- Track 3-4Bioinformatics in CADD.
- Track 3-5Ligand based CADD.
- Track 3-6Homology modeling.
Biomarkers are fast becoming an essential part of clinical development, because they offer a faster alternative to the conventional drug development approach and also safe drugs in greater number .The global market of biomarkers was valued at USD 23.9 billion in 2015 and the global market of biomarkers is expected to reach $45.55 billion by 2020 from $23.9, and at a CAGR of 13.58% between 2015 and 2020. Increasing health care expenditure & R&D spending and the increasing utility of biomarkers for diagnostics are expected to drive the market. On the other hand, the need for high capital investment, low benefit-cost ratio, poorly suited regulatory & reimbursement systems, and the high cost of tests and sample collection &and storage are the major factors restraining the growth of this market
- Track 4-1 Biomarker Discovery & Identification Strategies
- Track 4-2Clinical Applications of Cell-Free DNA & RNA in Disease Diagnosis & Management
- Track 4-3Cell-free DNA & RNA Technologies & Their Platforms
- Track 4-4Companion Diagnostics Development & Commercialization
- Track 4-5Clinical Trials & Developments
- Track 4-6Biomarkers in Clinical Development & Clinical Trials
- Track 4-7 Biomarkers in Diagnostics
- Track 4-8 Biomarkers in Personalized Medicine
- Track 4-9 Biomarkers of Translational Medicine: Safety, PK/PD, & Efficacy
- Track 4-10 Biomarkers from Qualification to Validation
- Track 4-11New Developments in Cell-Free Biomarkers
In the last few decades immunotherapy has become an important part of treating various diseases particularly in treating some types of cancer. Newer types of immune treatments are now being studied. In 2015, the global cancer immunotherapy market was valued at USD $37.50 billion, with its revenue expected to progress at a very strong CAGR of 14.6% with in a forecast period from 2016 to 2024, and the global cancer immunotherapy market is expected to reach USD $124.88 billion by the end of 2024. The Europe cancer immunotherapy market was worth $ 13.20 billion in 2016 and is estimated to reach $ 23.41 billion by the end of 2021 with growing potential of 12.45%.
- Track 5-1An NIH Perspective on Emerging Target Classes for Cancer Immunotherapy
- Track 5-2 Designing and Executing Cancer Immunotherapy Clinical Trials
- Track 5-3unicompetent Mouse Models as a Tool for Cancer Immunotherapy Pipeline Advancement
- Track 5-4 Biomarker Development for the Era of Combination Cancer Immunotherapy
- Track 5-5Rational Development of Combination Therapies in Immuno-Oncology
- Track 5-6Improving Immunotherapy with the HexaBody Platform
- Track 5-7Affinity and Epitope Interplay in Antibody Efficacy
- Track 5-8 Mechanisms of Action for the Application of BiTE Antibodies in Immunotherapy Combinations
- Track 5-9Hexavalent Single-Chain TNFSF-RBD-FC Fusion Proteins for Cancer Immunotherapy
- Track 5-10Emerging Predictive Biomarkers for Cancer Immunotherapy
- Track 5-11ADAPTIR Bispecifics, a Novel Platform for Development of Immuno-Oncology Therapeutics
- Track 5-12Mouse Models to Test Human Cancer Immuno-Therapeutics
Monoclonal antibodies have become important treatments for cancer, inflammation and a wide range of other diseases, representing an increasing share of the most successful pharmaceutical markets. Monoclonal antibodies (mAbs) are remarkably versatile protein molecules with numerous applications in human health. More than 30 mAb therapeutics have been approved for marketing and approximately 360 mAbs are currently in clinical studies, with 30 in pivotal trials. The global monoclonal antibodies (mAbs) market was valued at USD 85.4 billion in 2015 and is expected to reach a value of USD 138.6 billion by 2024, a growth rate of 5.7% over the forecast period.
- Track 6-1Antibody Protein Engineering
- Track 6-2Challenges in Antibody Discovery
- Track 6-3Antibody Drug Development
- Track 6-4Monoclonal antibody.
- Track 6-5Antibodies role in epigenetic.
- Track 6-6Polyclonal antibody.
New mass spectrometry (MS) methods, collectively known as data independent analysis and hyper reaction monitoring, have recently emerged. The analysis of peptides generated by photolytic digestion of proteins, known as bottom-up proteomics, serves as the basis for many of the protein research undertaken by mass spectrometry (MS) laboratories. Discovery-based or shotgun proteomics employs data-dependent acquisition (DDA). Herein, a hybrid mass spectrometer first performs a survey scan, from which the peptide ions with the intensity above a predefined threshold value, are stochastically selected, isolated and sequenced by product ion scanning. n targeted proteomics, selected environmental Monitoring (ERM), also known as multiple reaction monitoring (MRM), is used to monitor a number of selected precursor-fragment transitions of the targeted amino acids. The selection of the SRM transitions is normally calculated on the basis of the data acquired previously by product ion scanning, repository data in the public databases or based on a series of empirical rules predicting the Enzyme structure sites.The global spectroscopy market reached $ 13.5 billion in 2015 and it will reach to $ 15.6 billion in 2020 a Compound Annual Growth Rate [CAGR] of 2.9% through 2020.
- Track 7-1Types of Materials
- Track 7-2Innovations in Mass Spectrometry
- Track 7-3Mass Spectrometry in Metabolomics and Lipidomics
- Track 7-4Mass Spectrometry Configurations and Separation Techniques
- Track 7-5Mass spectrometry Imaging
- Track 7-6Fundamentals of Mass Spectrometry
- Track 7-7Mass Spectrometry in Proteome Research
- Track 7-8Integrated Strategies for Drug Discovery Using Mass Spectrometry
- Track 7-9Developments & Applications of Mass Spectroscopy
- Track 7-10Experimentation Tools in Mass Spectrometry
One of the most promising developments to come from the study of human genes and proteins has been the identification of potential new drugs for the treatment of disease. This relies on genome and proteome information to identify proteins associated with a disease, which computer software can then use as targets for new drugs. For example, if a certain protein is implicated in a disease, the 3D structure of that protein provides the information a computer programs needs to design drugs to interfere with the action of the protein.The global proteomics market is projected to reach USD 21.87 Billion by 2021, at a CAGR of 11.7% from 2016 to 2021.
- Track 8-1Emerging trends in proteomics
- Track 8-2Bioinformatics for proteomics
- Track 8-3Practical applications of proteomics
- Track 8-4Current research methodologies in Proteomics
- Track 8-5Strutural proteomics.
- Track 8-6Protein chips.
- Track 8-7Proteogenomics.
The discovery process includes the early phases of research, which are designed to identify an investigational drug and perform initial tests in the lab. This first stage of the process takes approximately three to six years. By the end, researchers hope to identify a promising drug candidate to further study in the lab and in animal models, and then in people.Pharmaceuticals represented a US$300 billion-a-year market globally as of 2015, the World Health Organization states. The global pharmaceutical market is expected to surpass US$400 billion by 2018.
- Track 9-1Successful Drug Discovery from the Research Lab to the Marketplace
- Track 9-2Recent Developments in Pharmaceutical Field
- Track 9-3Process Chemistry and Drug Manufacturing
Computational chemistry has become a useful way to investigate materials that are too difficult to find or too expensive to purchase. It also helps chemists make predictions before running the actual experiments so that they can be better prepared for making observations. Accuracy can always be improved with greater computational cost. Significant errors can present themselves in ab initio models comprising many electrons, due to the computational cost of full relativistic-inclusive methods. Other methods that are using in drug discovery are density functional methods, semi-empirical and empirical methods, molecular mechanics, methods of solids, chemical dynamics and molecular dynamics.The global market for computational medicine and drug discovery software was estimated to be $5.2 billion in 2015 and is projected to escalate to $7.1 billion by 2021.
- Track 10-1Theoretical chemistry
- Track 10-2Interpreting molecular wave functions
- Track 10-3Computational Methods
- Track 10-4Computational Accuracy
- Track 10-5Molecular mechanics.
- Track 10-6Chemical dynamics.
Today new biological targets, methodologies and advanced computing have improved modern drug discovery and have given medicinal chemistry a more profound skill set and toolkit to grasp the nuances of disease pathophysiology. The medicinal chemistry related approaches and methodologies in drug discovery increases the productivity in drug discovery and decrease attrition. Mainly in drug designing structure-based drug design, fragment –based drug design, natural product-based drug design, diversity-based drug design, and chemo genomics are applied.
- Track 11-1Medicinal Chemistry in drug designing
- Track 11-2Clinical Chemistry in drug discovery
- Track 11-3Electrochemistry in drug discovery
- Track 11-4Geochemistry in drug discovery and designing
- Track 11-5Analytical Chemistry in drug discovery
- Track 11-6Polymer Chemistry in drug designing
- Track 11-7Nuclear Chemistry in drug discovery and designing
- Track 11-8Advanced Organic Chemistry and Inorganic Chemistry in drug designing
- Track 11-9Quantum Chemistry in drug discovery
Pharmacology over the past 100 years has had a rich tradition of scientists with the ability to form qualitative or semi-quantitative relations between molecular structure and activity in cerebro. To test these hypotheses they have consistently used traditional pharmacology tools such as in vivo and in vitro models. Increasingly over the last decade however we have seen that computational (in silico) methods have been developed and applied to pharmacology hypothesis development and testing. These in silico methods include databases, quantitative structure-activity relationships, pharmacophores, homology models and other molecular modeling approaches, machine learning, data mining, network analysis tools and data analysis tools that use a computer. In silico methods are primarily used alongside the generation of in vitro data both to create the model and to test it.Drug Discovery Informatics Market size was USD 1.6 billion in 2015 and is anticipated to reach around USD 6.5 billion by 2023
- Track 12-1Insilico Cell models
- Track 12-2Insilico Drug Discovery with Virtual Screening
- Track 12-3Genetics
- Track 12-4Cellular model.
- Track 12-5Virtual affinity screening.
Nanotechnology has already begun to revolutionize medicine. Nanotechnology involves the use of materials with fundamental length scales in the nanometer dimension which demonstrate significantly changed properties compared to micron structured materials. Such materials can include particles, fibers, grain sizes, etc. This session highlighted the advancements nanotechnology is making in medicine in such fields as disease prevention, diagnosis, and treatment including (but not limited to) drug delivery, tissue engineering, implants, sensors, cancer treatment, and toxicity.The global market for nanoparticles in the life sciences is estimated at over $29.6 billion for 2014. This market is forecast to grow to more than $79.8 billion by 2019, to register a healthy compound annual growth rate (CAGR) of 22%.
- Track 13-1 Screening and design
- Track 13-2Nanotechnogy methods in Drug Design
- Track 13-3Nanotechnology Fundamental Concepts
- Track 13-4Current Research in Nanotechnology
- Track 13-5Nanomedicine.
- Track 13-6Nanometrology.
- Track 14-1Synthesis & Development techniques in Drug Discovery
- Track 14-2Drug Discovery Using Mass Spectrometry
- Track 14-3Innovative Strategies to Develop Drug Discovery
- Track 14-4High througput screening.
- Track 14-5 Phenotypic screening in drug discovery.
There is an impelling need to develop effective therapeutic strategies for patients with retinal disorders. From the past two decades on the mechanisms governing degeneration of the retina, it is now possible to devise innovative therapies based on retinal gene transfer. In gene transfer method we can correct the specific genetic defect in inherited retinal diseases, strategies to delay the onset of blindness independently of the disease-causing mutations and strategies to reactivate residual cells at late stages of the diseases. Under gene specific strategies like gene replacement for recessive inherited retinal disorder, gene-specific therapy for dominant inherited retinal disorders. Under non gene-specific therapies for ocular diseases mainly gene therapies modulating the secondary mechanisms of retinopathies, and optogenetics.The global ophthalmic drugs market was valued at US$16 bn in 2012 and is estimated to reach a market value of US$21.6 bn by 2018, rising at a CAGR of 5.2% from 2013 to 2018.
- Track 15-1Stem Cell and Gene Therapy for Ocular Diseases
- Track 15-2Combination Therapies for Ocular Diseases
- Track 15-3 Progress in Dry AMD – Research and Therapeutic Development
- Track 15-4Immunosuppressive therapy.
- Track 15-5Advanced cell technology[ACT].
- Track 15-6AAV-mediated gene therapy.